Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of ILS 18.65 million. The enterprise value is -1.25 million.

Market Cap	18.65M
Enterprise Value	-1.25M

Important Dates

The next estimated earnings date is Friday, August 14, 2026.

Earnings Date	Aug 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 1.86 billion shares outstanding. The number of shares has increased by 230.28% in one year.

Current Share Class	1.86B
Shares Outstanding	1.86B
Shares Change (YoY)	+230.28%
Shares Change (QoQ)	-21.85%
Owned by Insiders (%)	0.56%
Owned by Institutions (%)	17.89%
Float	1.85B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	0.61
P/TBV Ratio	2.50
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.02
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.06

Financial Position

The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.02.

Current Ratio	1.48
Quick Ratio	1.40
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -123.35% and return on invested capital (ROIC) is -22.91%.

Return on Equity (ROE)	-123.35%
Return on Assets (ROA)	-19.55%
Return on Invested Capital (ROIC)	-22.91%
Return on Capital Employed (ROCE)	-79.61%
Weighted Average Cost of Capital (WACC)	1.06%
Revenue Per Employee	n/a
Profits Per Employee	-8.21M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.61% in the last 52 weeks. The beta is -0.57, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.57
52-Week Price Change	-75.61%
50-Day Moving Average	1.01
200-Day Moving Average	1.85
Relative Strength Index (RSI)	40.99
Average Volume (20 Days)	368,621

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-186,281
Operating Income	-24.69M
Pretax Income	-82.48M
Net Income	-82.15M
EBITDA	-24.62M
EBIT	-24.69M
Earnings Per Share (EPS)	-0.06

Full Income Statement

Balance Sheet

The company has 20.29 million in cash and 580,943 in debt, with a net cash position of 19.71 million or 0.01 per share.

Cash & Cash Equivalents	20.29M
Total Debt	580,943
Net Cash	19.71M
Net Cash Per Share	0.01
Equity (Book Value)	30.51M
Book Value Per Share	0.02
Working Capital	6.90M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -21.47 million and capital expenditures -9,472, giving a free cash flow of -21.48 million.

Operating Cash Flow	-21.47M
Capital Expenditures	-9,472
Depreciation & Amortization	66,437
Net Borrowing	-644,147
Free Cash Flow	-21.48M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-230.28%
Shareholder Yield	-230.28%
Earnings Yield	-440.59%
FCF Yield	-115.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 6, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	1